166 related articles for article (PubMed ID: 30275913)
41. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
42. High expression level of BLCA-4 correlates with poor prognosis in human bladder cancer.
Zhao Q; Shen WH; Chen ZW; Zhou ZS; Ji HX
Int J Clin Exp Pathol; 2012; 5(5):422-7. PubMed ID: 22808294
[TBL] [Abstract][Full Text] [Related]
43. Serum irisin is a novel biomarker for bladder cancer detection.
Taken K; Aslan R; Eryilmaz R; Alp HH; Huyut Z; Dönmez Mİ
Int Urol Nephrol; 2022 Jan; 54(1):55-61. PubMed ID: 34807348
[TBL] [Abstract][Full Text] [Related]
44. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.
Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359
[TBL] [Abstract][Full Text] [Related]
45. Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladder.
Hori S; Miyake M; Onishi S; Tatsumi Y; Morizawa Y; Nakai Y; Anai S; Tanaka N; Fujimoto K
Oncol Rep; 2016 Oct; 36(4):2117-25. PubMed ID: 27573985
[TBL] [Abstract][Full Text] [Related]
46. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
47. Urinary protein biomarker panel for the detection of recurrent bladder cancer.
Rosser CJ; Chang M; Dai Y; Ross S; Mengual L; Alcaraz A; Goodison S
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1340-5. PubMed ID: 24714076
[TBL] [Abstract][Full Text] [Related]
48. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.
Cancel-Tassin G; Roupret M; Pinar U; Gaffory C; Vanie F; Ondet V; Compérat E; Cussenot O
World J Urol; 2021 Sep; 39(9):3329-3335. PubMed ID: 33770241
[TBL] [Abstract][Full Text] [Related]
49. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment.
Avgeris M; Mavridis K; Tokas T; Stravodimos K; Fragoulis EG; Scorilas A
Carcinogenesis; 2015 May; 36(5):528-37. PubMed ID: 25804644
[TBL] [Abstract][Full Text] [Related]
50. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
Zuiverloon TCM; de Jong FC; Theodorescu D
Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
[TBL] [Abstract][Full Text] [Related]
51. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
[TBL] [Abstract][Full Text] [Related]
52. Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study.
Yang H; Li H; Wang Z; Gao J; Guo Y
Urol Int; 2013; 91(4):456-61. PubMed ID: 23948854
[TBL] [Abstract][Full Text] [Related]
53. The determination of serum and urinary endocan concentrations in patients with bladder cancer.
Laloglu E; Aksoy H; Aksoy Y; Ozkaya F; Akcay F
Ann Clin Biochem; 2016 Nov; 53(6):647-653. PubMed ID: 26748103
[TBL] [Abstract][Full Text] [Related]
54. Comparison of cytology and nuclear matrix protein 22 (NMP 22) for the detection and follow-up of bladder-cancer.
Lahme S; Bichler KH; Feil G; Zumbrägel A; Götz T
Adv Exp Med Biol; 2003; 539(Pt A):111-9. PubMed ID: 15088900
[TBL] [Abstract][Full Text] [Related]
55. Overexpression of semaphorin 3A in patients with urothelial cancer.
Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
[TBL] [Abstract][Full Text] [Related]
56. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
57. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma.
Soukup V; Kalousová M; Capoun O; Sobotka R; Breyl Z; Pešl M; Zima T; Hanuš T
Urol Int; 2015; 95(1):56-64. PubMed ID: 25662337
[TBL] [Abstract][Full Text] [Related]
58. Ceruloplasmin Levels in Cancer Tissues and Urine Are Significant Biomarkers of Pathological Features and Outcome in Bladder Cancer.
Mukae Y; Ito H; Miyata Y; Araki K; Matsuda T; Aibara N; Nakamura Y; Matsuo T; Sakai H; Ohyama K
Anticancer Res; 2021 Aug; 41(8):3815-3823. PubMed ID: 34281841
[TBL] [Abstract][Full Text] [Related]
59. The clinical and prognostic value of miR-9 gene expression in Tunisian patients with bladder cancer.
Setti Boubaker N; Cicchillitti L; Said R; Gurtner A; Ayed H; Blel A; Karray O; Essid MA; Gharbi M; Bouzouita A; Rammeh Rommeni S; Chebil M; Piaggio G; Ouerhani S
Mol Biol Rep; 2019 Oct; 46(5):4743-4750. PubMed ID: 31214962
[TBL] [Abstract][Full Text] [Related]
60. [Value of detection of preoperative urinary soluble Fas expression in predicting the recurrence of non-muscle invasive bladder cancer].
Yang H; Guo Y; Wang Z; Wang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Jan; 41(1):24-9. PubMed ID: 26819421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
